Albumin Use in Patients With Cirrhosis in France: Results of the 'ALBU-LIVE' Survey
Autor: | Garioud, Armand, Cadranel, Jean-François, Pauwels, Arnaud, Nousbaum, Jean-Baptiste, Thévenot, Thierry, Dao, Thong, Louvet, Alexandre, Sogni, Philippe, Talbodec, Nathalie, Antonini, Teresa, Bureau, Christophe, Thabut, Dominique, Elkrief, Laure, Jouannaud, Vincent, Macaigne, Gilles, Bernard-Chabert, Brigitte, Lison, Hortensia, Alric, Laurent, Carbonell, Nicolas, Labadie, Héléne, Amiot, Xavier, Abergel, Armand, Hanslik, Bertrand, Leroy, Vincent, De Lédinghen, Victor, Denis, Jacques |
---|---|
Přispěvatelé: | Group Hospitalier public Sud Oise GHPSO (Creil), Centre Hospitalier de Gonesse, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Tourcoing, Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Raincy-Montfermeil, Centre Hospitalier Universitaire de Reims (CHU Reims), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), CHU Toulouse [Toulouse], CHU Saint-Antoine [AP-HP], Centre Hospitalier de Saint-Denis [Ile-de-France], CHU Clermont-Ferrand, Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Pessac, Centre Hospitalier Sud Francilien, CH Evry-Corbeil, Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Male
Human / administration & dosage [SDV]Life Sciences [q-bio] Practice Patterns Liver Cirrhosis / drug therapy Liver Cirrhosis / diagnosis Young Adult Human / adverse effects Liver Cirrhosis / complications Physicians' / trends Humans Guideline Adherence / trends Prospective Studies Serum Albumin Aged Physicians' / standards dult Infusions Intravenous Gastroenterologists / standards Middle Aged Treatment Outcome Health Care Surveys Gastroenterologists / trends Practice Guidelines as Topic Female France |
Zdroj: | Journal of Clinical Gastroenterology Journal of Clinical Gastroenterology, Lippincott, Williams & Wilkins, 2017, 51 (9), pp.831-838. ⟨10.1097/MCG.0000000000000735⟩ Journal of Clinical Gastroenterology, 2017, 51 (9), pp.831-838. ⟨10.1097/MCG.0000000000000735⟩ |
ISSN: | 0192-0790 |
DOI: | 10.1097/MCG.0000000000000735⟩ |
Popis: | International audience; IntroductionThe use of human albumin for the management of cirrhosis has increased. Recommendations have been published for therapeutic paracentesis (TP), spontaneous bacterial peritonitis (SBP), and type 1 hepatorenal syndrome (HRS). The goal of this survey was to assess the prescription practices of French hepatogastroenterologists.MethodsAll hepatogastroenterologists were contacted. The questionnaire evaluated (1) the use of albumin in validated indications and (2) the prescription of albumin for nonvalidated clinical situations.ResultsResponses were analyzed from 451 (50.1%) practitioners. The mean age was 40 years (range, 24 to 67 y). Physicians practiced in a university hospital (47.7%) or a general hospital (45.8%). There were 56.7% senior practitioners. Overall 99.6% of the practitioners compensated for TP. Albumin was used by 87.8% of the physicians, with a fixed dose being used by 84.6%. For SBP, 94% of the physicians used albumin concomitantly with antibiotics. The recommended protocol was followed by 56.2% of the practitioners: more often by senior university hospital practitioners than by senior general hospital practitioners (P=0.015). About 66.5% used albumin infusion for the diagnosis of HRS: used more often by senior university hospital practitioners (P=0.0006). Albumin was used concomitantly with vasopressor treatment by 84%; the dose and the duration varied considerably. About 23.5% used albumin for severe bacterial infection, 47.9% for severe hyponatremia, 43.9% for severe hypoalbuminemia, and 65.9% for hydrothorax.ConclusionsIn this large French survey, albumin is only prescribed in accordance with recommendations for TP. The schedule for SBP is followed by only 56% of the practitioners. The use of albumin for HRS is not adapted to recommendations, which are not well known, suggesting that they should be more diffused. |
Databáze: | OpenAIRE |
Externí odkaz: |